Shira M Goldenberg1, Julio Montaner2, Melissa Braschel3, Eugenia Socias2, Silvia Guillemi2, Kate Shannon2. 1. British Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, 608-1081 Burrard Street, Vancouver, BC, V6Z 1Y6, Canada; Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada. Electronic address: gshi-sg@cfenet.ubc.ca. 2. British Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, 608-1081 Burrard Street, Vancouver, BC, V6Z 1Y6, Canada; Department of Medicine, University of British Columbia, St. Paul's Hospital, Vancouver, BC, Canada. 3. British Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, 608-1081 Burrard Street, Vancouver, BC, V6Z 1Y6, Canada.
Abstract
BACKGROUND: Hepatitis C virus (HCV) represents a significant cause of morbidity and mortality globally. While sex workers may face elevated HCV risks through both drug and sexual pathways, incidence data among sex workers are severely lacking. HCV incidence and predictors of HCV seroconversion among women sex workers in Vancouver, BC were characterized in this study. METHODS: Questionnaire and serological data were drawn from a community-based cohort of women sex workers (2010-2014). Kaplan-Meier methods and Cox regression were used to model HCV incidence and predictors of time to HCV seroconversion. RESULTS: Among 759 sex workers, HCV prevalence was 42.7%. Among 292 baseline-seronegative sex workers, HCV incidence density was 3.84/100 person-years (PY), with higher rates among women using injection drugs (23.30/100 PY) and non-injection crack (6.27/100 PY), and those living with HIV (13.27/100 PY) or acute sexually transmitted infections (STIs) (5.10/100 PY). In Cox analyses adjusted for injection drug use, age (hazard ratio (HR) 0.94, 95% confidence interval (CI) 0.86-1.01), acute STI (HR 2.49, 95% CI 1.02-6.06), and non-injection crack use (HR 2.71, 95% CI 1.18-6.25) predicted time to HCV seroconversion. DISCUSSION: While HCV incidence was highest among women who inject drugs, STIs and the use of non-injection stimulants appear to be pathways to HCV infection, suggesting potential dual sexual/drug transmission. Integrated HCV services within sexual health and HIV/STI programs are recommended.
BACKGROUND:Hepatitis C virus (HCV) represents a significant cause of morbidity and mortality globally. While sex workers may face elevated HCV risks through both drug and sexual pathways, incidence data among sex workers are severely lacking. HCV incidence and predictors of HCV seroconversion among women sex workers in Vancouver, BC were characterized in this study. METHODS: Questionnaire and serological data were drawn from a community-based cohort of women sex workers (2010-2014). Kaplan-Meier methods and Cox regression were used to model HCV incidence and predictors of time to HCV seroconversion. RESULTS: Among 759 sex workers, HCV prevalence was 42.7%. Among 292 baseline-seronegative sex workers, HCV incidence density was 3.84/100 person-years (PY), with higher rates among women using injection drugs (23.30/100 PY) and non-injection crack (6.27/100 PY), and those living with HIV (13.27/100 PY) or acute sexually transmitted infections (STIs) (5.10/100 PY). In Cox analyses adjusted for injection drug use, age (hazard ratio (HR) 0.94, 95% confidence interval (CI) 0.86-1.01), acute STI (HR 2.49, 95% CI 1.02-6.06), and non-injection crack use (HR 2.71, 95% CI 1.18-6.25) predicted time to HCV seroconversion. DISCUSSION: While HCV incidence was highest among women who inject drugs, STIs and the use of non-injection stimulants appear to be pathways to HCV infection, suggesting potential dual sexual/drug transmission. Integrated HCV services within sexual health and HIV/STI programs are recommended.
Authors: A Uusküla; K Fischer; R Raudne; H Kilgi; R Krylov; M Salminen; H Brummer-Korvenkontio; J St Lawrence; S Aral Journal: Sex Transm Infect Date: 2008-02-06 Impact factor: 3.519
Authors: Kate Shannon; Steffanie A Strathdee; Shira M Goldenberg; Putu Duff; Peninah Mwangi; Maia Rusakova; Sushena Reza-Paul; Joseph Lau; Kathleen Deering; Michael R Pickles; Marie-Claude Boily Journal: Lancet Date: 2014-07-22 Impact factor: 79.321
Authors: Kimberly A Page-Shafer; Barbara Cahoon-Young; Jeffrey D Klausner; Scott Morrow; Fred Molitor; Juan Ruiz; Willi McFarland Journal: Am J Public Health Date: 2002-04 Impact factor: 9.308
Authors: Kimberly Page; Judith A Hahn; Jennifer Evans; Stephen Shiboski; Paula Lum; Eric Delwart; Leslie Tobler; William Andrews; Lia Avanesyan; Stewart Cooper; Michael P Busch Journal: J Infect Dis Date: 2009-10-15 Impact factor: 5.226
Authors: Toni Frederick; Pamela Burian; Norah Terrault; Mardge Cohen; Michael Augenbraun; Mary Young; Eric Seaberg; Jessica Justman; Alexandra M Levine; Wendy J Mack; Andrea Kovacs Journal: AIDS Patient Care STDS Date: 2009-11 Impact factor: 5.078
Authors: Kate Shannon; Melanie Rusch; Robert Morgan; Megan Oleson; Thomas Kerr; Mark W Tyndall Journal: Subst Use Misuse Date: 2008 Impact factor: 2.164
Authors: Linh-Vi N Le; Siobhan O'Connor; Tram Hong Tran; Lisa Maher; John Kaldor; Keith Sabin; Hoang Vu Tran; Quang Dai Tran; Van Anh Thi Ho; Tuan Anh Nguyen Journal: Western Pac Surveill Response J Date: 2019-07-25